Charles Schwab Investment Management Inc. Boosts Stock Position in Integer Holdings Co. (NYSE:ITGR)

Charles Schwab Investment Management Inc. grew its position in shares of Integer Holdings Co. (NYSE:ITGR) by 1.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 408,588 shares of the medical equipment provider’s stock after purchasing an additional 4,559 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.22% of Integer worth $54,146,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in ITGR. Eagle Asset Management Inc. purchased a new position in shares of Integer during the third quarter worth about $14,403,000. Laurus Investment Counsel Inc. acquired a new stake in shares of Integer during the fourth quarter worth about $5,422,000. New York State Common Retirement Fund boosted its stake in shares of Integer by 20.9% during the fourth quarter. New York State Common Retirement Fund now owns 232,569 shares of the medical equipment provider’s stock worth $30,820,000 after buying an additional 40,158 shares during the period. Bamco Inc. NY boosted its stake in shares of Integer by 17.4% during the third quarter. Bamco Inc. NY now owns 254,377 shares of the medical equipment provider’s stock worth $33,069,000 after buying an additional 37,700 shares during the period. Finally, Jane Street Group LLC boosted its stake in shares of Integer by 23.3% during the third quarter. Jane Street Group LLC now owns 151,397 shares of the medical equipment provider’s stock worth $19,682,000 after buying an additional 28,572 shares during the period. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Stock Performance

NYSE:ITGR opened at $118.41 on Friday. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $3.98 billion, a price-to-earnings ratio of 35.24, a PEG ratio of 1.72 and a beta of 1.24. The firm’s fifty day simple moving average is $134.43 and its 200 day simple moving average is $132.75. Integer Holdings Co. has a twelve month low of $107.11 and a twelve month high of $146.36.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). The business had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. As a group, equities research analysts expect that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ITGR shares. KeyCorp increased their target price on shares of Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Citigroup increased their target price on shares of Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 11th. Wells Fargo & Company restated an “overweight” rating and issued a $160.00 price objective on shares of Integer in a research report on Tuesday, December 3rd. Truist Financial raised their price objective on shares of Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Oppenheimer downgraded shares of Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Integer presently has an average rating of “Moderate Buy” and a consensus price target of $147.67.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.